U.S. Banks Stock News

If you are wondering whether Gen Digital is priced attractively right now, or if the recent volatility is a warning sign, this article focuses squarely on what the current share price might be implying. Over the short term, the stock has recent returns of 1.9% over 7 days, a 15.2% decline over 30 days, a 26.4% decline year to date, a 16.9% decline over 1 year, a 14.9% gain over 3 years, and a 1.2% decline over 5 years. Together, these figures give you a mixed picture of how sentiment has...

Event context and recent performance Lantheus Holdings (LNTH) has drawn fresh attention after its recent trading performance, with the stock up about 3% over the past week, 8% over the past month, and 13% in the past 3 months. See our latest analysis for Lantheus Holdings. At a share price of $78.08, Lantheus has seen short term momentum build with a 30 day share price return of 7.61% and year to date share price return of 16.07%. However, the 1 year total shareholder return of 16.41% and 3...

If you are wondering whether Academy Sports and Outdoors is attractively priced right now, the stock's recent track record and current valuation metrics offer a useful starting point for your own view. The share price closed at US$57.18 recently, with returns of 1.3% over 7 days, a 5.1% decline over 30 days, 9.6% year to date, 69.5% over 1 year, a 11.0% decline over 3 years, and 86.9% over 5 years. This gives you a range of outcomes to weigh. Recent coverage of Academy Sports and Outdoors...

If you are trying to work out whether Credit Acceptance at around US$444 per share looks expensive or offers value, the starting point is understanding what the current share price actually reflects. Over the last week the stock is up 5.0%, while the 1 year return sits at a 5.0% decline and the year to date move is a 2.0% decline, which hints that sentiment around risk and reward has shifted more than once recently. The share price moves sit against a backdrop of ongoing attention on...

Why Virgin Galactic’s latest filings and results are drawing attention Virgin Galactic Holdings (SPCE) has come back into focus after its fourth quarter and full year 2025 results, alongside a new shelf registration for common stock tied to an employee stock ownership plan. The company reported fourth quarter 2025 sales of US$0.312 million and a net loss of US$62.72 million, with full year sales of US$1.54 million and a net loss of US$278.91 million, prompting fresh interest in its capital...

If you are wondering whether WESCO International's share price still offers value, or if the easier gains have already been made, this article breaks down what the current price might be implying. The stock most recently closed at US$278.57, with returns of 1.8% over 7 days, 5.5% over 30 days, 10.5% year to date, 111.4% over 1 year, 110.0% over 3 years, and 232.4% over 5 years. Recent market attention around WESCO International has focused on its role as a key distributor in capital goods...

In early April 2026, NASA’s Orion spacecraft, built by Lockheed Martin, successfully launched the crewed Artemis II mission from Kennedy Space Center, carrying four astronauts on a 10-day journey around Earth and beyond the far side of the Moon with upgraded life support, controls, and safety systems. This mission highlights how Lockheed Martin’s space technology work sits alongside its expanding missile and aircraft programs, underscoring its role across both deep-space exploration and...

If you are wondering whether Clearway Energy's share price still offers value after a strong run, the key is understanding what the current market price might already be factoring in. The stock last closed at US$39.64, with returns of 1.2% over 7 days, 12.7% over 30 days, 23.4% year to date, 68.3% over 1 year, 58.3% over 3 years and 94.3% over 5 years. This raises the question of how much of the story is already reflected in the valuation. Recent news around Clearway Energy has focused on...

Investors may be wondering whether Sprouts Farmers Market is still priced attractively after recent volatility, or if the easy value has already been taken off the table. The stock closed at US$77.12, with returns of 0% over 7 days, a 3.9% decline over 30 days, a 4.4% decline year to date, a 46.7% decline over 1 year, but gains of 123.9% over 3 years and 182.9% over 5 years. Recent attention on Sprouts Farmers Market has focused on its longer term share price track record compared with more...

In 2025, nVent Electric benefited from surging data center demand for liquid cooling solutions and a recent acquisition that supported higher revenue, drawing praise in Mairs & Power Small Cap Fund’s fourth-quarter investor letter. The company also attracted increased hedge fund interest and favorable analyst attention, underscoring how its exposure to AI-driven infrastructure resonated with institutional investors. We’ll now examine how this stronger AI data center demand narrative may...

In its latest results, WillScot Holdings reported a 13% year-over-year decline in EBITDA, a similar drop in units on rent, and wrote off about 15% of its rental fleet, underscoring mounting financial and operational pressure. These fleet impairments and signs of tougher competition, particularly from United Rentals, point to a business mix tilting toward smaller, less profitable segments. Against this backdrop of fleet write-offs and weakening core metrics, we will assess how the news...

Spyre Therapeutics recently reported that it completed enrollment ahead of schedule for the rheumatoid arthritis cohort in its Phase 2 SKYWAY trial of SPY072, while CEO Cameron Turtle sold 15,000 shares under a pre-arranged Rule 10b5-1 trading plan and new employees received stock option inducement grants. This combination of faster-than-planned clinical progress and ongoing insider and employee equity activity highlights how drug development milestones and leadership incentives are evolving...

Why Brookfield Wealth Solutions is on investors’ radar today Brookfield Wealth Solutions (BNT) has been drawing attention after a period where the share price shows mixed returns across different time frames. This has prompted closer scrutiny of its business mix and current valuation. See our latest analysis for Brookfield Wealth Solutions. The latest 1 day share price return of a 0.4% decline and 90 day share price return of a 12% decline contrast with a 1 year total shareholder return of...

In recent weeks, Alliant Energy announced a US$1.00 billion at-the-market equity offering to fund data center and AI/cloud-related infrastructure, alongside governance changes such as a mandatory director retirement age of 70 and a target of 75% independent board representation. The same initiatives have drawn rising environmental and community opposition in Wisconsin and Iowa, highlighting that Alliant’s push into digital infrastructure could reshape both its growth profile and its...

What Enova International (ENVA) investors are watching now Enova International (ENVA) has drawn fresh attention as its recent share performance contrasts sharply between time frames, with a modest move over the past month alongside a 14% decline in the past 3 months. See our latest analysis for Enova International. At a share price of $138.77, Enova International’s recent 5.7% 7 day share price return contrasts with a 14.3% year to date share price decline. The 1 year total shareholder return...

Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted biologics license application for UX111, a gene therapy for Sanfilippo syndrome Type A, with an accelerated approval decision expected later this year. See our latest analysis for Ultragenyx Pharmaceutical. The FDA milestones around UX111 and UX016 have arrived against a mixed backdrop, with a sharp 18.5% 7 day share price return contrasting with a 1 year total shareholder return of 28.84% and a 5 year...

Corteva recently reached a new all-time high, supported by overwhelmingly positive analyst sentiment that now skews toward “Buy” ratings from major firms. Low short interest and strong participation from both Wall Street and individual investors highlight how sentiment alone can materially influence Corteva’s trading activity. We’ll now explore how this wave of bullish analyst support could reshape Corteva’s investment narrative and perceived risk-reward balance. This technology could...

Green Brick Partners (GRBK) is drawing fresh investor attention after announcing Rainwater Crossing, a master planned community in Celina, Texas that combines new model homes, multiple builders, extensive amenities and public art. See our latest analysis for Green Brick Partners. Alongside the Rainwater Crossing announcement, Green Brick Partners’ share price has moved to US$66.26, with a 7 day share price return of 5.59% but a 30 day share price return of a 3.00% decline. The 1 year total...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...

Crinetics Pharmaceuticals (CRNX) recently submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. See our latest analysis for Crinetics Pharmaceuticals. The Brazil filing arrives after a strong run in recent days, with a 7 day share price return of 10.01% partly offsetting a weaker year to date share price return of 19.32% and contrasting with a 1...

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...

Tractor Supply Company recently reported a softer fourth quarter, with revenue growing year on year but missing analysts’ expectations and leading management to issue full‑year earnings guidance and EBITDA that also came in below forecasts. In contrast, the company has continued to invest in community engagement, launching an FFA-exclusive contest for its 2026 Harvest Fest tote bag to support youth education and highlight its rural lifestyle brand. We’ll now examine how the recent earnings...

Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year. The sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company. With losses widening...